Swiss Biotech sector boosted by shift toward private funding, report says

Switzerland's biotech sector shifted toward private financing in 2025 as capital markets funding remained difficult to secure. The report also noted that pharmaceutical companies increased collaborative deals with biotech firms, suggesting a more defensive funding environment despite ongoing strategic partnering.

Analysis

Switzerland's biotech sector shifted toward private financing in 2025 as capital markets funding remained difficult to secure. The report also noted that pharmaceutical companies increased collaborative deals with biotech firms, suggesting a more defensive funding environment despite ongoing strategic partnering.